ROGER CRYSTAL
CIK 1656633 · Chief Executive Officer · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.08M
Companies
3
Total Filings
24
Lifetime Open-Market Net
-$2.05M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Director | 24,289 | $44.39 | $1.08M | $0 | 1 | 2026-06-15 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Director | 19,623 | $15.00 | $294.3K | $0 | 4 | 2025-06-16 |
| OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Chief Executive Officer | 6,667 | $20.65 | $137.7K | -$2.05M | 18 | 2023-03-03 |
Recent Filings · Page 2 of 3
24 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-29 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Grant (A) | +6,667 | $0 | EDGAR |
| 2022-01-27 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Sell (S) | −1,995 | -$52.2K | EDGAR |
| 2022-01-12 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Sell (S) | −1,058 | -$32.3K | EDGAR |
| 2022-01-05 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Grant (A) | +40,000 | $0 | EDGAR |
| 2021-09-16 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Buy (P) | +100 | $2.3K | EDGAR |
| 2021-01-27 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Grant (A) | +19,416 | $0 | EDGAR |
| 2020-01-09 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Grant (A) | +13,650 | $0 | EDGAR |
| 2019-04-08 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Mixed | −7,301 | -$190.6K | EDGAR |
| 2019-04-04 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Mixed | +7,301 | -$47.9K | EDGAR |
| 2019-01-17 | OPIANT PHARMACEUTICALS, INC. (OPNT) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.